| Title |
Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab
|
|---|---|
| Published in |
Biologics in Therapy, January 2013
|
| DOI | 10.1007/s13554-012-0006-1 |
| Pubmed ID | |
| Authors |
Pamela R. Puthoor, Edwin F. de Zoeten |
| Abstract |
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that has significant morbidities in the pediatric population. Goals of medical therapy include induction and maintenance of remission while preserving the colon and it's function, while minimizing the risk of treatment related morbidities. For those children who do not respond to initial therapies and progress to develop moderately-to-severely active UC, there has been a dearth of available treatments to help induce remission, necessitating long-term corticosteroid usage, with associated comorbidities of chronic steroid treatment. Significant advances have been made in medical management, including the use of biologic therapies, specifically anti-tumor necrosis factor-α monoclonal antibodies. With the Food and Drug Administration's recent approval of the use of infliximab, a chimeric anti-tumor necrosis factor-α antibody, for children ≥6 years of age with moderately-to-severely active UC, care providers now have a new treatment regimen to offer this pediatric population. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Chile | 1 | 2% |
| Unknown | 46 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 9 | 19% |
| Student > Postgraduate | 6 | 13% |
| Student > Ph. D. Student | 5 | 11% |
| Student > Master | 4 | 9% |
| Student > Bachelor | 3 | 6% |
| Other | 12 | 26% |
| Unknown | 8 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 43% |
| Agricultural and Biological Sciences | 4 | 9% |
| Nursing and Health Professions | 3 | 6% |
| Computer Science | 2 | 4% |
| Unspecified | 1 | 2% |
| Other | 6 | 13% |
| Unknown | 11 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 January 2013.
All research outputs
#18,327,422
of 22,694,633 outputs
Outputs from Biologics in Therapy
#12
of 20 outputs
Outputs of similar age
#217,934
of 280,642 outputs
Outputs of similar age from Biologics in Therapy
#1
of 1 outputs
Altmetric has tracked 22,694,633 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 20 research outputs from this source. They receive a mean Attention Score of 2.2. This one scored the same or higher as 8 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,642 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them